Lineage Cell Therapeutics, Inc. (LCTX) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
2173 SALK AVENUE CARLSBAD, CA 92008 |
| State of Incorp. | CA |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 47,805 | 35,492 | 57,875 | 58,400 | 41,600 | 30,700 | |||
| Cash and cash equivalent | 45,789 | 35,442 | 11,355 | 55,742 | 32,585 | 9,497 | |||
| Short-term investments | 2,016 | 50 | 46,520 | 2,616 | 8,977 | 21,219 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 42 | 38 | (16) | ||||||
| Restricted cash and investments | 581 | ||||||||
| Receivables | 638 | 745 | 23,896 | ||||||
| Other undisclosed current assets | 2,554 | 2,204 | 1,544 | 53,149 | 2,399 | 2,923 | |||
| Total current assets: | 50,997 | 38,441 | 60,000 | 111,549 | 43,999 | 57,519 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 2,144 | ||||||||
| Property, plant and equipment | 2,251 | 4,767 | 5,673 | 4,872 | 5,630 | 8,175 | |||
| Intangible assets, net (including goodwill) | 57,212 | 57,234 | 57,364 | 57,494 | 57,704 | 58,920 | |||
| Goodwill | 10,672 | 10,672 | 10,672 | 10,672 | 10,672 | 10,672 | |||
| Intangible assets, net (excluding goodwill) | 46,540 | 46,562 | 46,692 | 46,822 | 47,032 | 48,248 | |||
| Deposits noncurrent assets | 627 | 630 | 616 | 864 | |||||
| Restricted cash and investments | 565 | 550 | |||||||
| Other undisclosed noncurrent assets | 49 | 27 | |||||||
| Total noncurrent assets: | 62,221 | 62,578 | 63,664 | 62,996 | 63,950 | 67,959 | |||
| TOTAL ASSETS: | 113,218 | 101,019 | 123,664 | 174,545 | 107,949 | 125,478 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 5,437 | 6,270 | 8,608 | 27,969 | 6,813 | 5,226 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 2,162 | 1,959 | 1,549 | ||
| Accounts payable | 1,174 | 2,050 | 2,393 | 3,543 | 2,611 | 2,427 | |||
| Accrued liabilities | 1,197 | 1,097 | 3,833 | 22,086 | 1,711 | 1,246 | |||
| Other undisclosed accounts payable and accrued liabilities | 3,066 | 3,123 | 2,382 | 178 | 532 | 4 | |||
| Deferred revenue | 7,388 | 10,808 | 9,421 | 18,119 | 193 | 45 | |||
| Debt | 55 | 52 | 36 | 30 | 762 | 1,223 | |||
| Other undisclosed current liabilities | 1,097 | 830 | 916 | 998 | 1 | ||||
| Total current liabilities: | 13,977 | 17,960 | 18,981 | 47,116 | 7,769 | 6,494 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 67 | 91 | 84 | 1,971 | 2,540 | 3,945 | |||
| Finance lease, liability | 67 | 91 | 84 | 30 | 26 | 77 | |||
| Liabilities, other than long-term debt | 22,162 | 20,945 | 32,663 | 34,530 | 2,076 | 3,515 | |||
| Deferred revenue | 14,433 | 18,693 | 27,725 | 32,454 | 200 | ||||
| Deferred income tax liabilities | 273 | 273 | 2,076 | 2,076 | 2,076 | 3,315 | |||
| Other liabilities | 2 | ||||||||
| Operating lease, liability | 1,295 | 1,979 | 2,860 | 1,941 | 2,514 | 3,868 | |||
| Derivative instruments and hedges, liabilities | 6,161 | ||||||||
| Other undisclosed noncurrent liabilities | 30 | 437 | 277 | ||||||
| Total noncurrent liabilities: | 22,229 | 21,036 | 32,747 | 36,531 | 5,053 | 7,737 | |||
| Total liabilities: | 36,206 | 38,996 | 51,728 | 83,647 | 12,822 | 14,231 | |||
| Equity | |||||||||
| Equity, attributable to parent | 78,381 | 63,419 | 73,339 | 92,221 | 96,199 | 112,959 | |||
| Common stock | 484,722 | 451,343 | 440,280 | 434,529 | 393,944 | 387,062 | |||
| Accumulated other comprehensive loss | (2,876) | (3,068) | (3,571) | (5,211) | (3,667) | (681) | |||
| Accumulated deficit | (403,465) | (384,856) | (363,370) | (337,097) | (294,078) | (273,422) | |||
| Equity, attributable to noncontrolling interest | (1,369) | (1,396) | (1,403) | (1,323) | (1,072) | (1,712) | |||
| Total equity: | 77,012 | 62,023 | 71,936 | 90,898 | 95,127 | 111,247 | |||
| TOTAL LIABILITIES AND EQUITY: | 113,218 | 101,019 | 123,664 | 174,545 | 107,949 | 125,478 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 9,499 | 8,945 | 14,703 | 4,341 | 1,826 | 3,515 | ||
| Cost of revenue | (334) | (671) | (728) | (1,426) | (385) | (412) | ||
| Gross profit: | 9,165 | 8,274 | 13,975 | 2,915 | 1,441 | 3,103 | ||
| Operating expenses | (30,643) | (33,007) | (36,495) | (52,126) | (27,888) | (41,979) | ||
| Operating loss: | (21,478) | (24,733) | (22,520) | (49,211) | (26,447) | (38,876) | ||
| Nonoperating income (expense) | 2,896 | 1,451 | (3,292) | 5,941 | 4,523 | 19,642 | ||
| Other nonoperating income (expense) | (670) | (4) | (2,152) | 1,486 | 2,880 | 2,532 | ||
| Interest and debt expense | 523 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (18,582) | (23,282) | (25,812) | (42,747) | (21,924) | (19,234) | ||
| Other undisclosed loss from continuing operations before income taxes | (523) | |||||||
| Loss from continuing operations before income taxes: | (18,582) | (23,282) | (25,812) | (43,270) | (21,924) | (19,234) | ||
| Income tax expense (benefit) | 1,803 | (541) | 1,239 | (7,407) | ||||
| Loss from continuing operations: | (18,582) | (21,479) | (26,353) | (43,270) | (20,685) | (26,641) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (43,270) | (20,685) | (26,641) | |
| Other undisclosed net income | 14,814 | |||||||
| Net loss: | (18,582) | (21,479) | (26,353) | (43,270) | (20,685) | (11,827) | ||
| Net income (loss) attributable to noncontrolling interest | (27) | (7) | 80 | 251 | 36 | 118 | ||
| Net loss available to common stockholders, diluted: | (18,609) | (21,486) | (26,273) | (43,019) | (20,649) | (11,709) | ||
Comprehensive Income ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (18,582) | (21,479) | (26,353) | (43,270) | (20,685) | (11,827) | ||
| Other undisclosed comprehensive income (loss) | 192 | 503 | 1,640 | (1,544) | (2,986) | (2,107) | ||
| Comprehensive loss: | (18,390) | (20,976) | (24,713) | (44,814) | (23,671) | (13,934) | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | (27) | (7) | 80 | 251 | 36 | 118 | ||
| Comprehensive loss, net of tax, attributable to parent: | (18,417) | (20,983) | (24,633) | (44,563) | (23,635) | (13,816) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.